Company to host a conference call tomorrow at
8:00 a.m. ET
NEWTON,
Mass., Oct. 30, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced it will
host a conference call and audio webcast at 8:00 a.m. ET on
Thursday, October 31, 2024 to provide
a favorable study design update on the Company's pivotal Phase 3
SENTRY study in JAKi naive myelofibrosis.
The call will feature leading myelofibrosis key opinion leaders
Dr. Raajit Rampal, Director of the Center for Hematologic
Malignancies and Director of the Myeloproliferative Neoplasms
Program at Memorial Sloan Kettering Cancer Center and Dr. John
Mascarenhas, principal investigator of the Phase 3 SENTRY trial,
Professor of Medicine at the Icahn School of Medicine at Mount
Sinai and Director of the Center of Excellence for Blood Cancers
and Myeloid Disorders.
To access the conference call, please dial (800) 836-8184
(local) or (646) 357-8785 (international) at least 10 minutes prior
to the start time and ask to be joined into the Karyopharm
Therapeutics call. A live audio webcast of the call, along with
accompanying slides, will be available under "Events &
Presentations" in the Investor section of the Company's website,
http://investors.karyopharm.com/events-presentations. An archived
webcast will be available on the Company's website approximately
two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies is fueled by a belief in the
extraordinary strength and courage of patients with cancer. Since
its founding, Karyopharm has been an industry leader in oral
compounds that address nuclear export dysregulation, a fundamental
mechanism of oncogenesis. Karyopharm's lead compound and
first-in-class, oral exportin 1 (XPO1) inhibitor,
XPOVIO® (selinexor), is approved in the U.S. and
marketed by the Company in three oncology indications. It has also
received regulatory approvals in various indications in a growing
number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has a focused
pipeline targeting indications in multiple high unmet need cancers,
including in multiple myeloma, endometrial cancer, myelofibrosis,
and diffuse large B-cell lymphoma (DLBCL). For more information
about our people, science and pipeline, please visit
www.karyopharm.com, and follow us on LinkedIn and on X at
@Karyopharm.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-host-investor-event-with-leading-myelofibrosis-kols-and-provide-a-favorable-study-design-update-on-october-31-2024-302292050.html
SOURCE Karyopharm Therapeutics Inc.
